Rein Therapeutics, Inc. (RNTX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company's lead product candidate, LTI-03, is in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis (IPF). A second candidate, LTI-01, has been paused indefinitely. The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(6.4) million | $(12.2) million | $(12.3) million |
| Operating Expenses | $(6.1) million | $(11.3) million | $(12.5) million |
| Cash & Investments | $43.6 million (as of June 30, 2026) | ||
| Accumulated Deficit | $(413.5) million (as of June 30, 2026) |
Liquidity: As of June 30, 2026, the company held $8.5 million in cash and cash equivalents and $35.1 million in short-term and long-term investments. Management believes these resources are sufficient to fund operations into the first quarter of 2028.
Material Changes vs. Prior Period
- Capital Raise: In May 2026, the company completed an underwritten public offering of 57.5 million shares at $1.00 per share, generating gross proceeds of $57.5 million and net proceeds of approximately $53.1 million. This significantly increased cash reserves from $3.2 million at year-end 2025 to $43.6 million.
- Expense Reduction: Total operating expenses decreased by approximately $1.2 million year-over-year for the six-month period, primarily due to the timing of third-party CRO services and reduced stock-based compensation.
- Debt Repayment: The company repaid approximately $5.4 million in notes payable in May 2026 upon the closing of the equity offering.
- Warrant Liability: A new warrant liability of $3.7 million was recognized related to warrants issued in connection with the May 2026 offering.
Outlook, Risks, and Management Commentary
- Clinical Progress: The Phase 2 RENEW trial for LTI-03 dosed its first patient in March 2026. Interim data is anticipated in the fourth quarter of 2026. The trial aims to enroll approximately 120 patients globally.
- Strategic Pause: Development of LTI-01 remains paused indefinitely to prioritize resources for LTI-03.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of sufficient accounting personnel and inadequate procedures for timely financial statement preparation. Remediation efforts are ongoing.
- Risks: The company has no approved products and expects to incur losses for the foreseeable future. Future viability depends on raising additional capital and the success of the LTI-03 clinical trials.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that current funds ($43.6M) will sustain operations into Q1 2028, given the high burn rate of clinical trials.
- Internal Controls: Review the status of remediation for the disclosed material weaknesses in financial reporting controls.
- Dilution: Assess the impact of outstanding warrants (approx. 11.3 million shares) and convertible preferred stock (12.2 million shares) on future share count.
- Clinical Milestones: Monitor patient enrollment rates for the RENEW trial and the timing of the anticipated Q4 2026 interim data readout.
- Contractual Obligations: Note the $20.8 million master services agreement with a CRO for the Phase 2 trial and the potential for future funding needs if the trial scope expands.